Yinghua Wang, Ph.D. is an experienced leader in the pharmaceutical industry with strong expertise in immuno-oncology drug discovery. Dr. Wang joined Simnova Bio from Sanofi, where he built and supervised a research group and led global collaborations to develop novel biotherapeutics targeting tumor microenvironment. Previously, Dr. Wang was a PI at Regeneron Pharmaceuticals and headed a research team working on immunotherapy drug discovery for oncology and inflammation. Dr. Wang has extensive experience in pre-clinical research and management with responsibilities from project conception, target validation, lead selection to IND enabling studies. He has built productive partnerships and research collaborations and advanced multiple programs toward various milestones.
Prior to industry, Dr. Wang did his postdoctoral training at Harvard Medical School/Mass General Hospital, where he was an American Cancer Society Fellow and became an Instructor in Medicine. His research revealed a novel therapeutic opportunity for leukemia by targeting cellular metabolism. Dr. Wang obtained his Ph.D. degree in Immunology from Columbia University. Before that he graduated from Anhui University with a Bachelor’s degree in Biochemistry and did a graduate study in the University of Science and Technology of China.